Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|93|3|371-374

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.3, 2018-03, pp. : 371-374

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Blinatumomab Pharmacodynamics and Exposure–Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 2, 2018-02 ,pp. : 168-179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 120-124

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 89-90

Karger

Access to resources Recommend Favorite

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 193-196

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characterization of CD22 expression in acute lymphoblastic leukemia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 964-969

John Wiley & Sons Inc

Access to resources Recommend Favorite